How to... prepare a case or a scientific presentation

David García Azorín
Hospital Clínico de Valladolid, Spain
davilink@hotmail.com
Today’s overview
You never get a second chance to make a first impression.
My name is... and I come from...
Your attitude
How to... prepare a case or a scientific presentation

David García Azorín, MD, PhD, MSci, FEBN, FEHF

Member of the executive board, Spanish Society of Neurology
Secretary, European Union of Medical Specialists
Chairman, Secondary Headache, Special Interest Group, International Headache Society
Responsible for cooking and cleaning in my house
Lord commander of the imperial force
How to... prepare a case or a scientific presentation

David García Azorín, MD, PhD, MSci, FEBN, FEHF

Member of the executive board, Spanish Society of Neurology
Secretary, European Union of Medical Specialists
Chairman, Secondary Headache, Special Interest Group, International Headache Society
Responsible for cooking and cleaning in my house
Lord commander of the imperial force
## Conflicts of interest

<table>
<thead>
<tr>
<th>Type</th>
<th>Organization/company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advisory Boards</td>
<td>Allergan, Lundbeck, Teva</td>
</tr>
<tr>
<td>Speaker / Speakers Boards</td>
<td>Allergan, Eli Lilly, Novartis, Lundbeck, Chiesi, Teva, Abbvie</td>
</tr>
<tr>
<td>Consultant</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>Grant support for research or education</td>
<td>International Headache Society, Carlos III institute (Spain)</td>
</tr>
<tr>
<td>Editorial Board</td>
<td>Journal of Headache and Pain, Neurological Sciences</td>
</tr>
<tr>
<td>Author royalties</td>
<td></td>
</tr>
</tbody>
</table>
Your aspect
The audience
Visit the room!
Readable from backwards
The room
There are 118 causes of high-risk headache

• You must be vigilant and adapt the work-up to the suspected cause

Headache classification committee of the International headache society. *Cephalalgia* 2018;38:1-211
"The greatest teacher, failure is."

-Yoda
The slide support the speech
**K-Ras is currently the most effective clinically predictive biomarker**

- there are virtually no biomarkers that are useful in predicting response to treatment strategies; the best one at the present time is the presence of K-Ras mutations
- K-Ras is a key cell signaling molecule that acts downstream of receptor tyrosine kinases such as EGFR; activating K-Ras mutations occur in ~ 40% of CRC and K-Ras mutations are associated with poor prognosis and poor survival
- two anti-EGFR monoclonal antibody drugs, cetuximab and panitumumab, are ineffective in patients with activating K-Ras mutations; see McIntire et al pdf

**Too many words overwhelms & frustrates people – influence visually**

- A foam engine is needed to ensure a rapid response to fires and chemical releases. Risk engineering audits and tactical fire-fighting procedures require that foam suppression capabilities be maintained on site for flammable liquid type fires. The plant is a member of CIMA, which maintains by-laws for conditions of membership.
  These conditions of membership require that a minimum 1,250 gpm of foam solution is needed for flammable liquid type fires. In addition at least 1,000 gallons of foam storage capabilities are required. If a plant does not maintain an engine the loss of membership in CIMA is a realistic potential. This would result in a much lower response capability in the event of a major fire or spill at the site. In addition to providing fire-fighting and toxic gas suppression capability at the site an aerial would provide rescue capability to 100 feet. This aerial would also satisfy a risk engineering recommendation to provide aerial response to the site as well.
Key findings of the study

• Headache is uncommon in patients with infective endocarditis
• Its presence seems associated with neurological manifestations
• Patients with headache experience fewer amount of cardiac complications
Self-explanatory
...she has no other neurologic symptoms. She reports no numbness or tingling sensations. She denies any visual changes to vision. Past medical history includes gallbladder removal and past surgical history of diabetes, rheumatoid arthritis, hypertension, and hypothyroidism. Medications include advair albuterol allopurinol aspirin, clobetasol, folic acid, fosamax, lev oxyllis, oprimet, formineprazole, plaquenil, rednex, isetososterone, and pamlil. Allergies include aspirin and penicillin. Social history includes smoking, she does not smoke. She does not drink and does not use recreation alcohol. She weighs 150 pounds and is 5'8" tall. Her family history is negative for brain aneurysms or morther aneurysm. She was also negative for heart disease, high cholesterol, and hypertension. She was positive for diabetes. Review of systems shows positive for hypertension and swelling in the hands and feet, leg pain, while walking, asthma, pneumonia, shortness of breath, gastritis, ulcers, diabetes, thyroid disease, urinary tract infections, and those symptoms related to the present illness. The details of her review of systems were reviewed with the patient and are included in the surgical history questionnaire pain. The patient has episodic joint pain that is treated with tylenol. She does not have any nutritional concerns. She does not have any safety concerns. Physical examination...
Convince
Select the positive/key findings
Case #5: Saturday 28\textsuperscript{th} October, 2023

37 y.o. woman

No relevant prior history. Treatment with oral contraceptives

New onset headache, with progressive worsening, and resistant to acute treatments
Interaction
Case courtesy of Andrei Dumitrescu, Radiopaedia.org, rID: 152020
Reinforce the presented information / messages

Examples:
To sum up

- Multiple
- Menacing
- Frequent
- Mimicry
- Responsive to acute treatment
- But may have a specific treatment
Active
Positive
Short
Specific

Take-home messages
Thanks to the audience… and to your team/colleagues/mentors.
Answering questions

• Good question...

• I don’t know
García-Azorín D. Acute and preventive treatment of COVID-19 related headache: A series of 100 patients. EJON. Under evaluation
Thank you for your time

• David García Azorín
• davilink@hotmail.com